J Hematol

Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc

Journal website https://jh.elmerpub.com

Original Article

Volume 15, Number 3, June 2026, pages 156-161

Patterns and Outcomes of Recurrence in Pediatric Langerhans Cell Histiocytosis

Table

↓ **Table 1.** Clinical Characteristics and Outcomes of Pediatric Patients With Recurrent Langerhans Cell Histiocytosis
Patient	Sex	Age at initial diagnosis (months)	Time to first recurrence (months)	Initial risk stratification	Diabetes insipidus at diagnosis	Disease manifestation at recurrence	Treatment at recurrence	Complications during treatment	Number of recurrences	Current status	Follow-up from diagnosis (months)
1	Male	23	6	Multisystem RO+	Yes	Multifocal bone and skin involvement; MRI brain - pituitary stalk thickening	Cladribine + cytarabine (LCH-S protocol)	Febrile neutropenia - two episodes Respiratory support needed	1	CR2	114
2	Male	13	28	Single-system multifocal bone	No	Multifocal bone lesions	Cladribine + cytarabine in initial recurrence; Lenalidomide + dexamethasone in later recurrences	Initial recurrence: 1) Febrile neutropenia - three episodes; 2) Transfusion support Later recurrences: nil	3	CR4	169
3	Male	10	14	Multisystem RO− sclerosing cholangitis	No	Multifocal bone and skin involvement	Cladribine + cytarabine	Febrile neutropenia - two episodes	1	CR2	102
4	Male	16	18	Multisystem RO−	No	Multifocal bone lesions	Cladribine + cytarabine (LCH-S protocol)	Febrile neutropenia - one episode	1	CR2	135
5	Female	57	39	Multisystem RO−	Yes	Single-site bone lesion	Cladribine + cytarabine (LCH-S protocol)	Febrile neutropenia - one episode	1	CR2	112
6	Male	43	22	Multisystem RO−	Yes	Multifocal bone and skin involvement; MRI brain - absence of pituitary bright spot	Lenalidomide + dexamethasone	Nil	2	CR3	63
7	Male	8	42	Multisystem RO+	Yes	Single-site bone lesion	Surgery; cladribine + cytarabine	Nil	3	CR3	132